Discovery of 1,4-Dihydroxy-2-naphthoate Prenyltransferase Inhibitors: New Drug Leads for Multidrug-Resistant Gram-Positive Pathogens was written by Kurosu, Michio;Narayanasamy, Prabagaran;Biswas, Kallolmay;Dhiman, Rakesh;Crick, Dean C.. And the article was included in Journal of Medicinal Chemistry in 2007.Application of 21867-64-1 This article mentions the following:
Since utilization of menaquinone in the electron transport system is a characteristic of Gram-pos. organisms, the 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) inhibitors (I) and (II) act as selective antibacterial agents against organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE), and Mycobacterium spp. Growth of drug-resistant Gram-pos. organisms was sensitive to the MenA inhibitors, indicating that menaquinone synthesis is a valid new drug target in Gram-pos. organisms. In the experiment, the researchers used many compounds, for example, 1-Propylpiperazine (cas: 21867-64-1Application of 21867-64-1).
1-Propylpiperazine (cas: 21867-64-1) belongs to piperazine derivatives. Piperazine causes primary dermal irritation and skin burns at high concentrations. Piperazine also causes eye irritation in humans. Piperazines are very broad chemical group, covering a wide range of drugs from antidepressants to antihistamines. The connecting property of all these chemicals is the presence of a piperazine functional group.Application of 21867-64-1
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics